Choroidal Neovascularization-Pipeline Review, H1 2017

Choroidal Neovascularization-Pipeline Review, H1 2017


  • Products Id :- GMDHC9210IDB
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Choroidal Neovascularization-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization-Pipeline Review, H1 2017, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Choroidal Neovascularization-Overview

Choroidal Neovascularization-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Choroidal Neovascularization-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Choroidal Neovascularization-Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd

Formycon AG

Genentech Inc

Graybug Vision Inc

Lupin Ltd

Mabion SA

Navigen Inc

NovelMed Therapeutics Inc

Noxxon Pharma AG

Promedior Inc

Choroidal Neovascularization-Drug Profiles

ACX-107-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides for Ophthalmology and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ayuv-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Doxorubicin Pegylated-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Calreticulin for Choroidal Neovascularization-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAb-30D8-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-2729-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-9405-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-20-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRM-167-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7716-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Inflammation and Choroidal Neovascularization-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Target VEGF for Choroidal Neovascularization-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Choroidal Neovascularization-Dormant Projects

Choroidal Neovascularization-Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Choroidal Neovascularization, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Choroidal Neovascularization, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Choroidal Neovascularization-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Choroidal Neovascularization-Pipeline by Formycon AG, H1 2017

Choroidal Neovascularization-Pipeline by Genentech Inc, H1 2017

Choroidal Neovascularization-Pipeline by Graybug Vision Inc, H1 2017

Choroidal Neovascularization-Pipeline by Lupin Ltd, H1 2017

Choroidal Neovascularization-Pipeline by Mabion SA, H1 2017

Choroidal Neovascularization-Pipeline by Navigen Inc, H1 2017

Choroidal Neovascularization-Pipeline by NovelMed Therapeutics Inc, H1 2017

Choroidal Neovascularization-Pipeline by Noxxon Pharma AG, H1 2017

Choroidal Neovascularization-Pipeline by Promedior Inc, H1 2017

Choroidal Neovascularization-Dormant Projects, H1 2017

Choroidal Neovascularization-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd, Formycon AG, Genentech Inc, Graybug Vision Inc, Lupin Ltd, Mabion SA, Navigen Inc, NovelMed Therapeutics Inc, Noxxon Pharma AG, Promedior Inc

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com